Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in
subjects who have been on an atypical (second-generation) antipsychotic medication. The
investigators hypotheses are that patients who receive Lovaza will experience a significant
decrease in triglycerides from baseline. Secondary hypotheses include: Patients will
experience a significant decrease in total cholesterol, and Lovaza will be well tolerated.